

PATIENT TO FILL OUT

Section 1. Patient Information

Patient name (first, MI, last) _____ DOB _____ Gender F M
 Address _____ City _____
 State _____ ZIP _____ Preferred language (if not English) _____

Mobile phone (_____) _____ Preferred # Voicemail
 Best time to call 8–10AM 10AM–12PM 12–2PM 2–4PM 4–6PM 6–9PM

Email _____

Alternate phone (_____) _____ Preferred # Voicemail

I have read the **Text Messaging Consent in Section 8** and expressly consent to receive text messages by or on behalf of the Program.

Patient Authorizations

I have read and agree to the Patient Authorization to Use and Disclose Health Information included in Section 7.

I have read and agree to the Patient Certifications included in Section 8.

Patient Sign

(1 of 2) Patient signature/Legal representative if patient is <18 years _____ Date _____

Patient Sign

(2 of 2) Patient signature/Legal representative if patient is <18 years _____ Date _____

Printed name if signed by legal representative if patient is <18 years _____

Representative relationship to patient if patient is <18 years _____

Section 2. Household Income

Required if enrolling in the **DUPIXENT MyWay** Patient Assistance Program.

How many people live in your household? _____
 Please refer to Section 8, *Patient Certifications*, for additional information about the Patient Assistance Program.

What is your total annual household income? _____
 (Includes salary/wages, Social Security income, unemployment insurance benefits, disability income, any other income for the household.)

Section 3. Insurance Information

Patient has no insurance. (Please fill out Section 2.) Attached copies of front and back of primary prescription and medical cards.

Primary Rx insurance name _____
 Rx insurance phone (_____) _____
 Policy ID # _____ Group # _____
 Rx BIN # _____ Rx PCN # _____

Primary medical insurance name _____
 Insurance phone (_____) _____
 Policy ID # _____ Group # _____
 Policyholder name (first/last) _____
 Relationship to patient _____

I have already sent this prescription to the specialty pharmacy.
 By checking the box, I acknowledge **DUPIXENT MyWay** will not conduct a benefits verification. The specialty pharmacy is responsible for securing coverage on my patient's behalf.
 My preferred specialty pharmacy is _____ Phone (_____) _____ Fax (_____) _____

Section 4. Prescriber Information

Prescriber name _____
 Specialty _____
 Address _____
 City _____ State _____ ZIP _____
 Prescriber NPI # _____

Site/facility name _____
 Office contact name _____
 Office contact email _____
 Phone (_____) _____ Fax (_____) _____
 Tax ID # _____

Section 5. Diagnosis (Choose ONE)

Date of diagnosis ____/____/____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma Primary diagnosis
 J45.50 Severe persistent asthma, uncomplicated
 J45.40 Moderate persistent asthma, uncomplicated

Chronic rhinosinusitis with nasal polyposis Primary diagnosis
 J33.9 Nasal polyps, unspecified J33.0 Polyp of nasal cavity

Moderate-to-severe atopic dermatitis Primary diagnosis
 L20.9 Atopic dermatitis, unspecified L20.89 Other atopic dermatitis

Other ICD-10-CM code _____

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

! Prescriber to fill out **required prescription information on page 2**

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.

Patient Name	DOB
Prescriber Name	Prescriber Phone #
Prescriber Address	
NPI#	Prescriber State License # <small>(Required for prescribers in Puerto Rico only)</small>

Section 6a. DUPIXENT® (dupilumab) Prescription Information

For **COMMERCIALLY INSURED** patients, Quick Start may be able to provide DUPIXENT at no cost if there is a coverage delay. Fill out sections 6a and 6b completely to determine patient eligibility.

Rx: DUPIXENT® (dupilumab) (100 mg/0.67 mL, 200 mg/1.14 mL, or 300 mg/2 mL)

Prescription: New start Sample product provided Date ____/____/____

Device type (Choose ONE): Pre-filled syringe (100/200/300 mg) **OR** Pre-filled pen (200/300 mg) (for use in adolescents ≥12 years)

Known drug allergies _____

Qty: 1 pk (package of 2 syringes or 2 pens) Refills _____ Days' supply: _____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma	Patients aged ≥12 years	<input type="checkbox"/> Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15 OR <input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15
	Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis <input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15	
Moderate-to-severe atopic dermatitis	Patients aged 6-11 years: Weight: _____ kg (1 kg=2.2 lb)	Weight 15 kg to <30 kg <input type="checkbox"/> Initial and subsequent doses: 100 mg SIG: 1 (100 mg/0.67 mL) injection SQ every 2 weeks OR <input type="checkbox"/> Initial and subsequent doses: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 4 weeks Weight ≥30 kg <input type="checkbox"/> Initial and subsequent doses: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks For pediatric patients (6 to 11 years old) with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage as per pediatric atopic dermatitis which includes an initial loading dose.
	Patients aged ≥18 years	<input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15
Chronic rhinosinusitis with nasal polyposis	Patients aged 6-17 years: Weight: _____ kg (1 kg=2.2 lb)	Weight 15 kg to <30 kg <input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 4 weeks, starting on Day 29 Weight 30 kg to <60 kg <input type="checkbox"/> Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15 Weight ≥60 kg <input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 <input type="checkbox"/> Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15
	Patients aged ≥18 years	<input type="checkbox"/> Dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks

PRESCRIBER TO FILL OUT


Sign	_____	_____
Prescriber signature (No stamps) Dispense as written	Date	Prescriber signature (No stamps) Substitution permitted
		Date

Collaborating MD name _____ (Nurse practitioner/physician assistant) NPI # _____

My signature certifies that the person named on this form is my patient; the information provided on this application, to the best of my knowledge, is complete and accurate; that therapy with DUPIXENT is medically necessary; and that I have prescribed DUPIXENT to the patient named on this form for an FDA-approved indication. I understand that my patient's information provided to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (the "Alliance") is for the use of DUPIXENT MyWay solely to verify my patient's insurance coverage, to assess, if applicable, my patient's eligibility for patient assistance and other support programs; and to otherwise administer DUPIXENT MyWay for the patient. I certify that I have obtained my patient's written authorization in accordance with applicable state and Federal law, including the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, to provide the individually identifiable health information on this form to reimbursement support programs such as DUPIXENT MyWay for these purposes. If applicable, I authorize DUPIXENT MyWay to conduct a benefits investigation for my patient and to act on my behalf for the limited purpose of transmitting this prescription to the appropriate pharmacy designated by the patient per their benefit plan provided that, if this prescription is not so designated, DUPIXENT MyWay is authorized to transmit this prescription to a network pharmacy it selects or to the pharmacy otherwise indicated. I understand that any free product distributed through the DUPIXENT MyWay Patient Assistance Program is not contingent on any purchase obligations. I also understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. I consent to DUPIXENT MyWay contacting me by fax, mail, or email to provide additional information about DUPIXENT injection or DUPIXENT MyWay. I understand that DUPIXENT MyWay may revise, change, or terminate any program services at any time without notice to me.

If you are a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.



Patient Name	DOB
Prescriber Name	Prescriber Phone #
Prescriber Address	
NPI#	Prescriber State License # <small>(Required for prescribers in Puerto Rico only)</small>

Section 6b. DUPIXENT® (dupilumab) Quick Start Program Prescription Information (For COMMERCIALY INSURED Patients)

For COMMERCIALY INSURED patients, Quick Start may be able to provide DUPIXENT at no cost if there is a coverage delay. Fill out sections 6a and 6b completely to determine patient eligibility.

Rx: DUPIXENT® (dupilumab) (100 mg/0.67 mL, 200 mg/1.14 mL, or 300 mg/2 mL)

Prescription: New start Sample product provided Date ____/____/____

Device type (Choose ONE): Pre-filled syringe (100/200/300 mg) **OR** Pre-filled pen (200/300 mg) (for use in adolescents ≥12 years)

Known drug allergies _____

Qty: 1 pk (package of 2 syringes or 2 pens) Refills _____ Days' supply: _____

Moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma

Patients aged ≥12 years

- Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15
- OR**
- Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis

- Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Patients aged 6-11 years:

Weight:

kg (1 kg=2.2 lb)

- Weight 15 kg to <30 kg**
- Initial and subsequent doses: 100 mg SIG: 1 (100 mg/0.67 mL) injection SQ every 2 weeks
- OR**
- Initial and subsequent doses: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 4 weeks

- Weight ≥30 kg**
- Initial and subsequent doses: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks

For pediatric patients (6 to 11 years old) with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage as per pediatric atopic dermatitis which includes an initial loading dose.

Moderate-to-severe atopic dermatitis

Patients aged ≥18 years

- Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Patients aged 6-17 years:

Weight:

kg (1 kg=2.2 lb)

- Weight 15 kg to <30 kg**
- Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 4 weeks, starting on Day 29
- Weight 30 kg to <60 kg**
- Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15
- Weight ≥60 kg**
- Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
- Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Chronic rhinosinusitis with nasal polyposis

Patients aged ≥18 years

- Dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks

Sign

Prescriber signature (No stamps) Dispense as written

Date

Prescriber signature (No stamps) Substitution permitted

Date

Collaborating MD name _____ (Nurse practitioner/physician assistant) NPI # _____

I authorize for my commercially insured patient one or more months of temporary shipments of DUPIXENT during a benefits determination delay or during the appeal process after an initial coverage delay for DUPIXENT by the patient's insurer. I authorize DUPIXENT MyWay to forward this prescription to the pharmacy dispensing the DUPIXENT Quick Start Program product to the patient named herein. I agree to assist in efforts to secure access to DUPIXENT for my commercially insured patient in the event of a coverage delay.

If you are a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please see accompanying full Prescribing Information or visit DUPIXENThcp.com.

PRESCRIBER TO FILL OUT

Section 7. Authorization to Use and Disclose Health Information

Patient: Please read the following carefully, then date and sign where indicated in Section 1 on page 1

I authorize my healthcare providers and staff (together, “Healthcare Providers”), my health insurer, health plan or programs that provide me healthcare benefits (together, “Health Insurers”), and any specialty pharmacies (“Specialty Pharmacies”) that dispense my medication to disclose to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together, the “Alliance”) health information about me, including information related to my medical condition and treatment, health insurance coverage and claims, and prescription (including fill/refill information) related to my prescription for *DUPIXENT*® (dupilumab) therapy (“My Information”). I understand the disclosure to the Alliance will be for the purposes of enrolling me in, and providing certain services through the “*DUPIXENT MyWay Program*,” including:

- to determine if I am eligible to participate in *DUPIXENT MyWay* coverage assistance programs, patient assistance programs, or other support programs
- to investigate my health insurance coverage for *DUPIXENT* injection
- to obtain prior authorization for coverage
- to assist with appeals of denied claims for coverage
- for the operation and administration of the *DUPIXENT MyWay Program*
- to refer me to, or to determine my eligibility for, other programs, or alternative sources of funding or coverage that may be available to provide assistance to me with the costs of my medication
 - I understand that the Alliance may de-identify My Information and use it in performing research, education, business analytics, marketing studies, or for other commercial purposes, including linkage with other de-identified information the Alliance receives from other sources. I understand that members of the Alliance may share My Information, including identifiable health information, among themselves in order to de-identify it for these purposes and as needed to perform the Services or to communicate with me by mail, telephone, or email, or, if I indicate my agreement and consent in Section 1 on page 1, by text. I understand and agree that the Alliance may use My Information for these purposes and may share My Information with my Healthcare Providers, Health Insurers and Specialty Pharmacies.
 - I understand and agree that my Healthcare Providers, Health Insurers, and Specialty Pharmacies may receive remuneration from the Alliance in exchange for disclosing My Information to the Alliance and/or for providing me with support services in connection with the *DUPIXENT MyWay Program*.

Once My Information has been disclosed to the Alliance, I understand that federal privacy laws may no longer protect it from further disclosure. However, I also understand the Alliance has agreed to protect My Information by using and disclosing it only for the purposes allowed by me in this Authorization or as otherwise required by law.

I understand that I do not have to sign this Authorization. A decision by me not to sign this Authorization will not affect my ability to obtain medical treatment, payment for treatment, insurance coverage, access to health benefits or Alliance medications from covered entities such as Health Care Providers, Health Insurers, and Specialty Pharmacies. However, if I do not sign this Authorization, I understand that I will not be able to participate in the *DUPIXENT MyWay Program*.

I understand that this Authorization expires 18 months from the date support is last provided under the Program, or until my local state law requires expiration, subject to applicable law, unless and until I withdraw (take back) this Authorization before then, or as otherwise required by law. Further, I understand that I may withdraw this Authorization at any time by mailing or faxing a written request to *DUPIXENT MyWay* at 1800 Innovation Point, Fort Mill, SC 29715; Fax: 1-844-387-9370. Withdrawal of this Authorization will end my participation in the *DUPIXENT MyWay Program* and will not affect any disclosure of My Information based on this Authorization made before my request is received and processed by my Healthcare Providers, Health Insurers, and Specialty Pharmacies.

I understand that I may request a copy of this Authorization.

Section 8. Patient Certifications

Patient: Please read the following carefully, then date and sign where indicated in **Section 1** on page 1

I am enrolling in the **DUPIXENT MyWay** Program (the “Program”) and authorize Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together the “Alliance”) to provide me services under the Program, as described in the Program Enrollment Form and as may be added in the future. Such services include medication and adherence communications and support, medication dispensing support, coverage and financial assistance support, disease and medication education, injection training, and other support services (the “Services”).

If enrolling in the **DUPIXENT MyWay** Copay Card Program, I understand that Copay Card information will be sent to my designated specialty pharmacy along with my prescription, and any assistance with my applicable cost-sharing or copayment for **DUPIXENT**® (dupilumab) injection will be made in accordance with the Program terms and conditions.

If I am completing Section 2, I certify that the information I have set forth in Section 2, including my household income, is true and accurate to the best of my knowledge. I also agree that the “Alliance” may verify my eligibility for the **DUPIXENT MyWay** Patient Assistance Program, and I understand that such verification may include contacting me or my healthcare provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I authorize the Alliance under the Fair Credit Reporting Act to use my demographic information to access reports on my individual credit history from consumer reporting agencies. I understand that, upon request, the Alliance will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize the Alliance to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources, to estimate my income in conjunction with the Patient Assistance Program eligibility determination process, if applicable. I further understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. If approved for the **DUPIXENT MyWay** Patient Assistance Program, I will not seek to have the value of any medication provided to me under this program counted toward my true-out-of-pocket (TrOOP) cost for prescription drugs for my Medicare Part D Plan. Continuation in the **DUPIXENT MyWay** Patient Assistance Program is conditioned upon timely verification of income. In addition, I agree to notify **DUPIXENT MyWay** if my insurance situation changes.

I authorize the Alliance to contact me by mail, telephone, or email, or, if I indicate my agreement and consent on page 1, by text,^a with information about the Program, disease state and products, promotions, services, and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys (together, the “Communications”). I understand that I may be contacted by the Alliance in the event that I report an adverse event. I understand that I do not have to enroll in the Program or receive the Communications, and that I can still receive **DUPIXENT** injection, as prescribed by my Healthcare Provider. I may opt out of receiving Communications, individual support services offered by the Program, including the **DUPIXENT MyWay** Copay Card, or opt out of the Program entirely at any time by notifying a Program representative by telephone at 1-844-387-4936 or by sending a letter to **DUPIXENT MyWay**, 1800 Innovation Point, Fort Mill, SC 29715. I also understand that the Services may be revised, changed, or terminated at any time.

I understand that my health information, contact information, and other information I, my healthcare provider, and others share with Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together the “Alliance”) is collected to provide me with the assistance I request and for other business purposes of the Alliance, as described in their privacy policy, which is available at regeneron.com/privacy-policy. Depending on where I live, I may have certain rights with respect to my privacy information, including the request to access or delete my personal information. I am aware that Regeneron may not be required to fulfill my requests in certain circumstances. I understand that to exercise these rights, I may contact the Privacy Office by emailing dataprotection@regeneron.com or by calling 844-835-4137. I may reference Sanofi’s Global Privacy Policy at sanofi.com/our-responsibility/sanofi-global-privacy-policy for further information regarding these rights with respect to Sanofi US.

Text Messaging Consent:

^aI acknowledge that by checking the Text Messaging Consent box on page 1, I expressly consent to receive text messages from or on behalf of the Program at the mobile telephone number(s) that I provide.

I confirm that I am the subscriber for the mobile telephone number(s) provided, and I agree to notify the Alliance promptly if any of my number(s) change in the future. I understand that my wireless service provider’s message and data rates may apply. I understand that I can opt out of future text messages at any time by texting SMSSTOP to 39771 from my mobile phone, and that I can get help for text messages by texting SMSHELP to 39771. I also understand that additional text messaging terms and conditions may be provided to me in the future as part of an opt-in confirmation text message. Message and data rates may apply.

I understand that my consent is not required as a condition of purchasing any goods or services from Regeneron Pharmaceuticals, Inc., Sanofi US, or their affiliates.

You may keep a copy of this form for your records.